Business UpdateJun 22, 2026, 10:32 AM
Cosmos Health's Cana Labs Secures 25M+ Unit Orderbook; $10M Profit
AI Summary
Cosmos Health's wholly owned subsidiary, Cana Laboratories, has secured a cumulative contract manufacturing orderbook exceeding 25 million units through multi-year agreements, some extending up to ten years. This division is expected to generate over $10 million in recurring annual profit at full capacity. The orders are diversified across nine therapeutic categories and will be produced at Cana's EU-GMP-licensed Athens facility, which recently underwent an approximately $5.5 million upgrade.
Key Highlights
- Cana Laboratories secured a cumulative contract manufacturing orderbook of over 25 million units.
- The contract manufacturing division is projected to generate over $10 million in recurring annual profit at full capacity.
- Multi-year agreements extend up to 10 years, providing long-term revenue visibility.
- Orderbook is diversified across nine therapeutic categories, reducing product dependence.
- Cana's Athens facility received an approximately $5.5 million upgrade, including a new capsule-filling line.
- Orders include 13.4 million units for Provident Pharmaceuticals.
- Orders include 4.36 million units for Pharmex S.A.
Price Impact
More from COSM